Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
Laurent Peyrin BirouletSeverine VermeireGeert D'HaensJulian PanesAxel U DignassFernando MagroMaciej NazarManuela Le BarsMarjolein LahayeLioudmila NiIvana BravatàFrederic LavieMarco DapernoMilan LukášAlessandro ArmuzziMark LöwenbergDaniel R GayaSilvio DanesePublished in: Alimentary pharmacology & therapeutics (2023)
STARDUST LTE is the first interventional ustekinumab efficacy study to show a favourable benefit-risk profile with preservation of clinical and endoscopic outcomes through Week 104 using flexible, algorithm-driven dose adjustment including de-escalation.